Study Objectives: Adaptive servo-ventilation (ASV) devices provide anticyclic pressure support for the treatment of central and/or complex sleep apnea, including heart failure patients. Variability in responses in the clinic and negative clinical trials motivated assessment of standard and novel signal biomarkers for ASV efficacy.
Introduction
The pathophysiology of sleep apnea is now well-established to extend beyond a collapsible airway [1, 2] . Driving mechanisms that cause an elevated apnea-hypopnea index (AHI) include airway collapsibility, impaired negative pressure response, low arousal threshold, and high loop gain. These phenotypes can coexist, especially high loop gain and low arousal threshold [1] [2] [3] . In most reports of periodic breathing, central sleep apnea or complex and treatment-emergent central sleep apnea, the standard sleep quality metrics show a disproportionate elevation of N1, low sleep efficiency, and even low total sleep time, regardless of positive airway pressure treatment subtypes (continuous, bilevel, and adaptive) [4] . This group of sleep apnea syndromes, considered collectively to be more than pure obstructive disease, exhibits a predominance of respiratory abnormality during nonrapid eye movement (NREM) sleep [3, 5] . Arousals during NREM sleep have an effect of amplifying the severity of this form of sleep apnea in particular [6] . Thus, it is difficult to establish a predominance of stable breathing in patients with high loop gain sleep apnea with continuous positive airway pressure (CPAP).
High loop gain sleep causes several polysomnographic patterns, central sleep apnea, periodic breathing, treatment-emergent (complex) sleep apnea, and high altitude periodic breathing. High loop gain drives much of the sleep apnea seen in heart failure patients. Adaptive servo-ventilation (ASV) is preferred over CPAP for therapy of high loop gain sleep apnea [7, 8] . Although CPAP can be of benefit if there is a substantial obstructive component, residual events persist in many patients (especially those with certain risk factors such as heart failure or opiate use), and ultimately, emergence of central apneas or periodic breathing occurs with rising pressures [5] . Adaptive ventilators are essentially anticyclic pressure support devices which provide equal and opposite degrees, timing, and rhythm of pressure support [8] . If such pressure can cause effective cancellation of high loop gain driving mechanisms by reducing and finally eliminating hypoventilation-hyperventilation cycles, stabilization of ventilation and sleep should occur (and the machine "rests" in either CPAP or BiPAP base mode). However, if this "noise cancellation" serves only to normalize respiratory patterns on the surface without stabilizing the underlying oscillations in ventilatory drive, periodic oscillations in respiratory drive may continue, resulting in patient-ventilator desynchrony, and manifest as ongoing pressure cycling. This situation is undesirable, due to possible adverse accompanying hemodynamic and EEG-arousal sequelae, which can adversely affect sleep quality, sleep hemodynamics, ventilation, and airflow. Although ASV devices are generally superior to CPAP in improving respiratory and sleep parameters, physician and patient users of these devices are aware of instances of variability in device efficacy. Bench testing protocols of ASV including varying combinations of obstructive and central respiratory events have shown a lack of stable breathing patterns and continued cycling of delivered pressures [9] . ASV devices are capable of inducing patient-ventilator desynchrony [10] .
Typical polysomnographic or ASV device-derived measures of efficacy may not be optimal for assessing efficacy of these devices with complex algorithms. The Complex Apnea Resolution Study, which randomized complex sleep apnea participants to CPAP versus ASV, demonstrated superiority in reduction of the AHI in the ASV arm, although polysomnographically estimated sleep fragmentation persisting in both arms, and sleepiness or quality of life, was not different [11] . The Treatment of Predominant Central Sleep Apnea by ASV in Patients With Heart Failure (Serve-HF) study reported increased mortality in patients with low ejection fraction and predominantly central sleep apnea, and no improvement in a wide range of secondary endpoints [12] . While there are many possible reasons for failure of the SERVE-HF trial [13, 14] , it is plausible that adaptive PAP for high loop gain sleep apnea may succeed in stabilizing sleep and respiration only in a subset of patients. The results of the Cardiovascular Outcomes With Minute Ventilation-Targeted ASV Therapy in Heart Failure (CAT-HF) Trial, evaluating the ResMed adaptive ventilator in hospitalized heart failure patients with moderate-to-severe sleep apnea, showed that ASV did not improve 6 month cardiovascular outcomes [15] . However, this trial was stopped early after the SERVE-HF results. Moreover, the best currently recognized biomarkers of treatment efficacy such as sleep stages and conventional respiratory events during polysomnography or the positive therapy device-estimated apnea-hypopnea index (AHI FLOW ) may fall short. In contrast to straightforward obstructive sleep apnea where suppression of AHI is a reliable marker of treatment success, the metric of reduction in AHI alone as a marker of efficacious control of disease in central apnea phenotypes during ASV use may be providing a false sense of reassurance [16] .
Our core hypothesis is that during ASV titration and clinical use, both conventional and novel signal biomarkers may be extractible from readily available sources. To test this hypothesis, we analyzed data from three sources: (1) archived polysomnograms (PSGs) from an American Academy of Sleep Medicine accredited sleep center; (2) a retrospective evaluation of waveform data from online data repositories; and (3) a detailed analysis of waveforms using data available from device Secure Digital (SD) cards using SleepyHead freeware.
Methods

Overview
The study used several sources of archived data and one set of current cross-sectional data during active use of ASV. Institutional Review Board approval was obtained for review of clinical, device, and polysomnographic data. Both Philips and ResMed data were included in PSG and data card analysis. There were too few data sets available from the Philips ASV (less than 20) to provide an adequate sample size for long-term tracking through the online systems. Several factors influenced our ability to obtain complete data sets (from diagnostic PSGs through home waveforms), including the following: (1) rapid reduction in ASV titrations and discontinuation of ASV in patients with heart failure after the availability of SERVE-HF data; (2) sudden closure of the two sleep centers performing all the PSGs for the BIDMC sleep center in 2010-2011, with inability to further access raw data and ultimately reports; (3) inability to obtain the raw signals for studies performed outside of BIDMC; (4) low rate of laboratory evaluations of ASV resulting in low long-term use (reasons included insurance coverage and early ASV intolerance); (6) multiple modes of therapy attempted on a single night (e.g. continuous, nonadaptive bilevel, ASV); and (7) regular use of online compliance data with indefinite (life-long) tracking started only in 2012. An internal audit after the SERVE-HF study news resulted in identifying about 450 patients who had ever been initiated on an ASV at our center, and only a fraction had current online data in AirView.
ASV laboratory titrations
Complex algorithms drive the ASV devices. The manufacturer's default settings were never used. Instead, careful titrations were done adjusting expiratory (and when available later in the evolution of the devices, minimum and maximum expiratory pressures) and typically constraining the difference between minimum and maximum inspiratory pressure support to 5 cm, unless clear cut inspiratory flow limitation or snoring was noted, which resulted in an increase in inspiratory pressure support. Titrations typically evaluated setting containing zero and 2-3 cm minimum pressure support. Technician training was performed by the co-author R.J.T., who personally attended at least a third of the titrations described in this report. Our center kept up with the most recent algorithms. All the data for review using SleepyHead were performed on the current algorithms, which included auto-EPAP and the ability to evaluate a minimum pressure support of zero.
Databases
Despite the limitations noted above, the following databases were available for review: (1) adaptive ventilation titrations: 108, of which 66 had mainstream ETCO 2 measurements; (2) AirView data in 98 participants; (3) complete data, from diagnostic PSG through review and analysis using SleepyHead freeware, in 44 participants; and (4) hemodynamic data in the form of beat-to-beat fingertip blood pressure during ASV titration, using a Finometer, in five participants. The participants described in the titration and AirView groups were nonoverlapping except for seven participants. Databases were selected to enable assessment whether sleep fragmentation or arousals were disproportionate to respiratory abnormality during ASV titrations, if ASV could induce hypocapnia, if pressure cycling was present during titrations, and persisted chronically. No specific inclusion or exclusion criteria were used other than the presence of central and complex apnea needing ASV use. Qualification criteria required a central AHI ≥ 5 per hour of sleep, and central events ≥ 50 per cent of all events. Our participants included those with heart failure, and a small fraction were on chronic opiate use, as summarized in the tables. All patients had failed CPAP either in the sleep laboratory during attended titration or during home use, with residual central sleep apnea.
PSG analysis
Scoring utilized updated American Academy of Sleep Medicine guidelines including sleep stages and respiratory events, respiratory effort-related arousals (RERAs), and central hypopneas (http://www.aasmnet.org/scoringmanual/default.aspx). Mainstream End-Tidal CO 2 enabled estimation of CO 2 steady state levels during ASV use, when the signal shows a stable plateau and absent respiratory events. Two further types of features were characterized as follows: (1) 
AirView data review
The online system was accessed and all participants with active transmission were tabulated using the following criteria: (1) a minimum of 2 hr use average per night and (2) a minimum of 6 months of device use. The following data, computed by the online system for the most recent 30 days, were extracted ( Table 1) : hours of use, ASV-derived AHI (50 per cent tidal volume reduction events, AHI TV ), minute ventilation, respiratory rate and tidal volume (MV, RR, and TV, respectively) median, and 95th percentiles. Finally, the MV, TV, and RR ratios (95th percentile divided by the median as a measure of fluctuations about the median) were computed. Pearson's correlations with machine-derived AHI were generated, under the assumption that a higher ratio would correlate with greater residual abnormal respiration.
SleepyHead data review
SleepyHead is a freeware software (https://sleepyhead.jedimark. net/) which enables review of data stored on SD cards retrieved from positive pressure therapy devices [16] . A wealth of information not available in the online systems such as AirView and EncoreAnywhere can be extracted or viewed from the SD cards, including flow, pressure, leak, inspiratory and expiratory times, and mean and median of respiratory rate, tidal volume, and minute ventilation [16] .
To estimate the proportion of stable breathing during ASV therapy, three consecutive nights were evaluated for periods with and without pressure cycling (Figures 4-6 ). These are readily identified on the pressure output channel as periods of minimal pressure oscillations vs. periods where the pressure oscillates between the minimum and maximum pressure-support settings. Using SleepyHead in this manner is cumbersome, needing to use calipers or scales to manually estimate the proportion of pressure cycling.
Hemodynamic data
Beat-to-beat blood pressure recording was obtained using a Finometer during ASV titrations in five participants, selected for vulnerability to ASV-induced harm (heart failure) at the time of recording. The system alternates inflation of finger cuffs and has a calibration brachial cuff. The output was directly input into the PSG system (Nihon-Kohden), enabling assessment of blood pressure fluctuations associated with ASV-related pressure cycling (Figures 7-9 ).
Clinical impact of ASV pressure cycling
A review of the most recent clinical note was used to estimate the Clinical Global Impression-Improvement scale (CGI-I), a 7-point scale that requires an assessment of improvement or worsening relative to the beginning of treatment. The scale is as follows: very much improved, much improved, minimally improved, no change, minimally worse, much worse, and very much worse. The Epworth Sleepiness Scale was not documented for about half of the participant in the follow-up clinical notes.
Statistical methods
Summary metrics were mean, standard deviation, medians, and 95th percentile values for relevant measures. Intraclass coefficients were computed across three nights for variables extracted from the SD card. Paired variables used t-tests. Pearson correlation was estimated for machine-estimated AHI and ventilatory metrics from the AirView data. STATA12 was used for all analysis.
Results
ASV titrations
A total of 108 whole night ASV titrations were retrieved from the PSG archive. The majority were ResMed ASV (88), the rest Philips ASV. Table 2 is a summary of the data, with notable attributes being (1) male predominance, (2) low sleep efficiency, (3) elevated N1, and (4) 
AirView data
There were 98 patients who fulfilled inclusion criteria, the majority (72.5 per cent) were male, with substantial durations of use (24 ± 6.2 months). The ASV-estimated AHI was 4 ± 5.3 per hour of use (average 305.7 ± 135.4 min). Table 1 summarizes the derived respiratory metrics, with statistically significant correlations of the ASV-AHI with tidal volume, respiratory rate, and minute ventilation ratios. The highest correlation (r: 0.60) was with the minute ventilation ratio, which is a composite of the tidal volume and respiratory rate.
SleepyHead data analysis
There were 44 participants with PSG data, and available SD cards to review; five were treated with Philips BiPAP Auto SV Advanced. Table 3 shows the patient characteristics, including male dominance, moderately elevated body mass index, and comorbid hypertension. Twenty-five per cent of this group had atrial fibrillation. Therapies included use of hypocapnia minimization with a nonvented mask in 22 patients and acetazolamide in eight patients. Table 4 summarizes the PSG data. Notable features include a persistently low sleep efficiency, reduced N3%, and a persistently high arousal index. Table 5 summarizes the metrics extracted from the SD card. The intraclass coefficients were high for a range of metrics, consistent with night-to-night stability at least over the three nights of evaluation (Table 5) .
Predictors of pressure cycling
Using a threshold of 50 per cent stable breathing, 13/44 (29.6 per cent) had predominantly stable breathing. With the caveat of a low number of devices (5/55), the Philips BiPAP Auto SV Advanced had less pressure cycling than the ResMed Adaptive ventilator (66.8 vs. 32.9 per cent, t-test p: 0.006). No polysomnogram or demographic characteristics predicted high pressure cycling, except the following: (1) all 11 patients with atrial fibrillation were in the high pressure cycling group, 82.3 vs. 56.5 per cent, t-test p: 0.004) with or without the arrhythmia, and (2) those receiving acetazolamide had a markedly increased probability of being in the low pressure cycling group, odds ratio 9.8, p: 0.015 [CI:1.56-61.5], after adjustment for age, gender, race, diabetes, hypertension, ischemic heart disease, and ischemic cerebrovascular disease.
Hemodynamic effects of ASV pressure cycling
Five participants (three males, age: 59 ± 7.2 years, diagnostic PSG: AHI3% and arousal 44.8 ± 11.4, CAHI 23.4 ± 6.9 per hour of sleep) were evaluated for part of the night (183 ± 23.6 min, average). Of this recording duration, stable breathing periods were 92.6 ± 22.5 min, average. One hundred twenty pressure cycling events were analyzed-the mean arterial pressure in the preceding 15 s was 82 ± 7.2 mm Hg with a mean increase of 22 ± 12 mm Hg associated with the pressure events.
Clinical correlates of pressure cycling
The clinical global impression improvement scale showed significant correlations with the percentage of pressure cycling (r: −0.62, p: 0.01) and minute ventilation ratios (r: −0.58, p: 0.03), with higher amounts of pressure cycling and higher MV ratios associated with less clinical improvement in symptoms.
Discussion
The key results of our analysis are as follows: (1) There is a substantial residual polysomnographic abnormality across multiple dimensions (sleep and respiration) during ASV evaluations, including hypocapnia. (2) The ASV device can induce pressure cycling, which in turn can be associated with undesirable hemodynamic changes. (3) Persistent respiratory abnormality during home use is common and easily recognized. (4) This persistent respiratory abnormality is moderately correlated with global clinical outcomes. (5) Beyond the device-estimated AHI FLOW , several measures extracted from the device have the potential for use in longitudinal tracking of responses. The high intraclass coefficients for AHI and other extractable metrics are consistent with stability of patterns over multiple nights. The single best metric, which associated with pressure cycling and was stable night to night, was the ratio of the 95th percentile to the median tidal volume ratio.
ASV algorithms are complex, and some of the variability, in the literature, of clinical responses, may reflect using default algorithms of the manufacturers, or using a fixed EPAP. Our center has kept up with the most updated algorithms, and only a minority (estimate is less than 20 per cent in our report) was first-generation devices. These complex algorithms also interact with numerous other factors to generate a pressure cycling response-including arousals from other etiologies, mask leak, sleep-wake transitions, and phasic REM sleep. Thus, not all what is noted as pressure cycling is harmful or generated solely by the ASV device. We excluded data with large leaks. Patients with periodic breathing or central sleep apnea have a high propensity for arousals and sleep fragmentation, which likely contributed to some of the pressure cycling seen.
Our results show that the ResMed ASV machine calculations of raw residual AHI FLOW are relatively insensitive to pressure cycling. The correlation of AHIFLOW with pressure cycling was lower than that obtained by minute ventilation (0.49 vs. 0.63). Moreover, patients with stable breathing and minimal pressure cycling or with entire nights of pressure cycling but tidal volume fluctuations less than 50 per cent could both have very low machine AHI values, e.g. 0-5. SERVE-HF used the criteria of machine AHI ≤ 10 per hour to define adequate control of sleep apnea, and it is possible that many participants with values less than 10 had substantial ongoing pressure cycling. It is notable that even after "successful" titration on ASV with reduction in AHI, there were persistently elevated arousal indices, poor sleep continuity, and elevations in blood pressure in our estimations. Improvements in AHI and normalization of airflow have commonly been accepted as surrogate markers of improvement in sleep quality, but if those improvements come at the cost of inducing patient-device desynchrony, with associated microarousals and surges in autonomic activity, the trade-off is suboptimal. There may be potential for harm from poorly effective ASV therapy. The guidelines used to estimate the efficacy of continuous or nonadaptive bilevel may not be optimal for ASV devices, and new measures such as those described in this report require prospective testing with adequate sample size. Polysomnographic correlates of pressure cycling include sleep fragmentation, arousals, and blood pressure fluctuations. During chronic outpatient management, surrogate evaluation methods could include ambulatory blood pressure monitoring, sleep quality estimates using technologies such as cardiopulmonary coupling [17] , or raw data evaluation from SD cards which are in principle available universally. The presence or absence of pressure cycling is not easy to assess reviewing data on AirView, even with the current version of the software, which shows a low-resolution pressure trace. Moreover, subjectivity remains a problem to estimate pressure cycling in compressed online views. High MV ratios can be a clue, which would prompt further investigation of the data using the SD card with SleepyHead software, where the presence or absence of concerning degrees of pressure cycling becomes obviously apparent on quick visual inspection. The subset of patients found to have severe pressure cycling and desynchrony can then undergo further titration or evaluation of adjunctive therapies such as acetazolamide [18, 19] , oxygen [20, 21] , sedatives [22, 23] , or hypocapnia minimization [24] , to attempt to identify pressure settings that allow improvements in sleep quality and hemodynamics. The MV ratio is a metric which could be easily tracked online over time, providing a dynamic and longitudinal measure of respiratory stability even when the AHI values are in a "normal" range.
Tracking and adjustments could improve clinical symptoms, identify responders and nonresponders, and enable personalized management plans to be tailored more precisely. In the interim, automated analysis of waveforms, leak, and correlates with patient diaries or self-reported factors will help translate these insights into care decisions. Among those patients who may be asymptomatic or whose symptoms do not match standard metrics, biomarkers of biological impact may be the only window into treatment effectiveness.
The following potential mechanisms of patient-ventilator desynchrony and persistent pressure cycling are speculative, but biologically plausible. Loop gain may be too high for the device algorithm to compensate or correct. Variable obstructive features may add to variability of tidal or flow volumes sensed by these devices and trigger or sustain pressure cycling. Induction of hypocapnia can worsen respiratory control instability. Arousals associated with pressure cycling can amplify loop gain and desynchrony effects. Analogous to pacemaker-loop arrhythmias [25] , it is possible that the ventilator's oscillatory output algorithm loops with circulation time and controller gain to cause a perpetual cycle during periods of unstable NREM sleep. Some patients find the sensation of ASV-related pressure oscillations uncomfortable, which may prolong sleep-wake transitional instability and enhance pressure cycling. Some of these challenges, though unlikely all, can be addressed in principle with improved machine algorithms. Reduced pressure cycling in users of acetazolamide (itself started likely for excessive pressure cycling) suggests that persistent and unresolved high loop gain effects drive at least some of the pressure cycling.
The limitations of our analysis include relatively small sample size, and components of the data were incomplete due to reasons noted. Data heterogeneity does not allow clear conclusions but generate hypotheses which would need to be tested in larger prospective data sets. Our method of extraction from SleepyHead objectively is cumbersome, using calipers or scale and manually tabulating consecutive nights. In the clinic, we simply view the data and make a visual estimate, which seems concordant at least in members of our sleep center. It should be possible for the manufacturers to provide RR/TV/MV metrics within the online systems, to enable tracking over time.
Detailed clinical outcomes were not the focus of this evaluation. Hemodynamic measures were available on a very small subset. Central and complex apnea patients are generally the hardest clinical group to treat, and optimal target end points are not known. Thus, it may be unrealistic to expect mostly stable breathing, as can be readily achieved in patents with straightforward obstructive sleep apnea. We have no reason to believe that the problems and findings noted here are unique to any specific ASV device, but our results provide support for more advanced signal analysis and data presentation for review, using an extended range of data, including pressure cycling.
In conclusion, we show that an ASV device can be associated with persistently unstable respiration during polysomnograhic titrations and long-term therapeutic use. The ASV algorithm may in some instances contribute to disruption of sleep, but numerous reasons for persistent and excessive pressure cycling exist. The ASV estimate AHI FLOW can be misleading when values are in the "normal" range, and other measures of respiratory stability such as percentage of pressure cycling or minute ventilation kinetics may be more informative biomarkers of treatment response. Further investigation to correlate these markers with long-term clinical outcomes is needed.
